A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo

Yuan Wu Chen, Hsu Shan Huang, Yi Shing Shieh, Kuo Hsing Ma, Shing Hwa Huang, Dueng Yuan Hueng, Huey Kang Sytwu, Gu Jiun Lin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Oral squamous cell carcinoma (OSCC) is a prevalent cancer, especially in developing countries. Anthracyclines and their anthraquinone derivatives, such as doxorubicin, exhibit a cell growth inhibitory effect and have been used as anti-cancer drugs for many years. However, the cardiotoxicity of anthracycline antibiotics is a major concern in their clinical application. NSC745885 is a novel compound synthesized from 1,2-diaminoanthraquinone, which subsequently reacts with thionyl chloride and triethylamine. The present study aimed to investigate the anti-oral cancer potential and the safety of NSC745885. Methods: We investigated the anti-cancer potential of NSC745885 in oral squamous carcinoma cell lines and in an in vivo oral cancer xenograft mouse model. The expression of apoptotic related genes were evaluated by real-time RT-PCR and western bloting, and the in vivo assessment of apoptotic marker were measured by immunohistochemical staining. The anti-tumor efficiency and safety between doxorubicin and NSC745885 were also compared. Results: Our results demonstrated that NSC745885 exhibits anti-oral cancer activity through the induction of apoptosis in cancer cells and in tumor-bearing mice, and this treatment did not induce marked toxicity in experimental mice. This compound also exhibits a comparable anti-tumor efficiency and a higher safety in experimental mice when compared to doxorubicin. Conclusions: The data of this study provide evidence for NSC745885 as a potential novel therapeutic drug for the treatment of human OSCC.

Original languageEnglish
Article numbere104703
JournalPLoS One
Volume9
Issue number8
DOIs
Publication statusPublished - Aug 15 2014

Fingerprint

Tongue Neoplasms
tongue
Doxorubicin
Tumors
Anthracyclines
doxorubicin
neoplasms
anthracyclines
Bearings (structural)
mouth
Mouth Neoplasms
squamous cell carcinoma
Anthraquinones
Neoplasms
Squamous Cell Carcinoma
Cell growth
mice
Developing countries
Heterografts
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo. / Chen, Yuan Wu; Huang, Hsu Shan; Shieh, Yi Shing; Ma, Kuo Hsing; Huang, Shing Hwa; Hueng, Dueng Yuan; Sytwu, Huey Kang; Lin, Gu Jiun.

In: PLoS One, Vol. 9, No. 8, e104703, 15.08.2014.

Research output: Contribution to journalArticle

Chen, Yuan Wu ; Huang, Hsu Shan ; Shieh, Yi Shing ; Ma, Kuo Hsing ; Huang, Shing Hwa ; Hueng, Dueng Yuan ; Sytwu, Huey Kang ; Lin, Gu Jiun. / A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo. In: PLoS One. 2014 ; Vol. 9, No. 8.
@article{f72bb621f23b4e0f8f31919426e05f3b,
title = "A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo",
abstract = "Objective: Oral squamous cell carcinoma (OSCC) is a prevalent cancer, especially in developing countries. Anthracyclines and their anthraquinone derivatives, such as doxorubicin, exhibit a cell growth inhibitory effect and have been used as anti-cancer drugs for many years. However, the cardiotoxicity of anthracycline antibiotics is a major concern in their clinical application. NSC745885 is a novel compound synthesized from 1,2-diaminoanthraquinone, which subsequently reacts with thionyl chloride and triethylamine. The present study aimed to investigate the anti-oral cancer potential and the safety of NSC745885. Methods: We investigated the anti-cancer potential of NSC745885 in oral squamous carcinoma cell lines and in an in vivo oral cancer xenograft mouse model. The expression of apoptotic related genes were evaluated by real-time RT-PCR and western bloting, and the in vivo assessment of apoptotic marker were measured by immunohistochemical staining. The anti-tumor efficiency and safety between doxorubicin and NSC745885 were also compared. Results: Our results demonstrated that NSC745885 exhibits anti-oral cancer activity through the induction of apoptosis in cancer cells and in tumor-bearing mice, and this treatment did not induce marked toxicity in experimental mice. This compound also exhibits a comparable anti-tumor efficiency and a higher safety in experimental mice when compared to doxorubicin. Conclusions: The data of this study provide evidence for NSC745885 as a potential novel therapeutic drug for the treatment of human OSCC.",
author = "Chen, {Yuan Wu} and Huang, {Hsu Shan} and Shieh, {Yi Shing} and Ma, {Kuo Hsing} and Huang, {Shing Hwa} and Hueng, {Dueng Yuan} and Sytwu, {Huey Kang} and Lin, {Gu Jiun}",
year = "2014",
month = "8",
day = "15",
doi = "10.1371/journal.pone.0104703",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo

AU - Chen, Yuan Wu

AU - Huang, Hsu Shan

AU - Shieh, Yi Shing

AU - Ma, Kuo Hsing

AU - Huang, Shing Hwa

AU - Hueng, Dueng Yuan

AU - Sytwu, Huey Kang

AU - Lin, Gu Jiun

PY - 2014/8/15

Y1 - 2014/8/15

N2 - Objective: Oral squamous cell carcinoma (OSCC) is a prevalent cancer, especially in developing countries. Anthracyclines and their anthraquinone derivatives, such as doxorubicin, exhibit a cell growth inhibitory effect and have been used as anti-cancer drugs for many years. However, the cardiotoxicity of anthracycline antibiotics is a major concern in their clinical application. NSC745885 is a novel compound synthesized from 1,2-diaminoanthraquinone, which subsequently reacts with thionyl chloride and triethylamine. The present study aimed to investigate the anti-oral cancer potential and the safety of NSC745885. Methods: We investigated the anti-cancer potential of NSC745885 in oral squamous carcinoma cell lines and in an in vivo oral cancer xenograft mouse model. The expression of apoptotic related genes were evaluated by real-time RT-PCR and western bloting, and the in vivo assessment of apoptotic marker were measured by immunohistochemical staining. The anti-tumor efficiency and safety between doxorubicin and NSC745885 were also compared. Results: Our results demonstrated that NSC745885 exhibits anti-oral cancer activity through the induction of apoptosis in cancer cells and in tumor-bearing mice, and this treatment did not induce marked toxicity in experimental mice. This compound also exhibits a comparable anti-tumor efficiency and a higher safety in experimental mice when compared to doxorubicin. Conclusions: The data of this study provide evidence for NSC745885 as a potential novel therapeutic drug for the treatment of human OSCC.

AB - Objective: Oral squamous cell carcinoma (OSCC) is a prevalent cancer, especially in developing countries. Anthracyclines and their anthraquinone derivatives, such as doxorubicin, exhibit a cell growth inhibitory effect and have been used as anti-cancer drugs for many years. However, the cardiotoxicity of anthracycline antibiotics is a major concern in their clinical application. NSC745885 is a novel compound synthesized from 1,2-diaminoanthraquinone, which subsequently reacts with thionyl chloride and triethylamine. The present study aimed to investigate the anti-oral cancer potential and the safety of NSC745885. Methods: We investigated the anti-cancer potential of NSC745885 in oral squamous carcinoma cell lines and in an in vivo oral cancer xenograft mouse model. The expression of apoptotic related genes were evaluated by real-time RT-PCR and western bloting, and the in vivo assessment of apoptotic marker were measured by immunohistochemical staining. The anti-tumor efficiency and safety between doxorubicin and NSC745885 were also compared. Results: Our results demonstrated that NSC745885 exhibits anti-oral cancer activity through the induction of apoptosis in cancer cells and in tumor-bearing mice, and this treatment did not induce marked toxicity in experimental mice. This compound also exhibits a comparable anti-tumor efficiency and a higher safety in experimental mice when compared to doxorubicin. Conclusions: The data of this study provide evidence for NSC745885 as a potential novel therapeutic drug for the treatment of human OSCC.

UR - http://www.scopus.com/inward/record.url?scp=84915813756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915813756&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0104703

DO - 10.1371/journal.pone.0104703

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e104703

ER -